I agree that this site is using cookies. You can find further informations here.
X
Chau, I.
1438  results:
Search for persons X
?
1

399P A Quality-adjusted Time Without Symptoms and Toxicity ..:

Chau, I. ; Bridgewater, J.A. ; Wyrwicz, L.S....
Annals of Oncology.  35 (2024)  - p. S162 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Phase II trial of domatinostat (4SC-202) in combination wit..:

Cartwright, E. ; Slater, S. ; Saffery, C....
ESMO Open.  9 (2024)  4 - p. 102971 , 2024
Link: https://doi.org/10.1016/..
 
?
3

37P Phase II results of the porcupine (PORCN) inhibitor zam..:

Cook, N. ; Bridgewater, J.A. ; Saunders, M.P....
Annals of Oncology.  35 (2024)  - p. S19-S20 , 2024
Link: https://doi.org/10.1016/..
 
?
4

124P Acquired resistance to first-line chemo- and EGFRab-th..:

Lane, R. ; Mencel, J. ; Turkes, F....
Annals of Oncology.  35 (2024)  - p. S58 , 2024
Link: https://doi.org/10.1016/..
 
?
5

28P A mixed methods longitudinal process evaluation and imp..:

Hainsworth, E. ; Stapleton, S. ; Ogara, G....
Annals of Oncology.  35 (2024)  - p. S14 , 2024
Link: https://doi.org/10.1016/..
 
?
6

30P Immunological markers of pathological and clinical and ..:

Challoner, B.R. ; Slater, S.C. ; Sansano, H.B....
Annals of Oncology.  35 (2024)  - p. S15 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Maintenance durvalumab after first-line chemotherapy in pat..:

Fong, C. ; Patel, B. ; Peckitt, C....
ESMO Open.  9 (2024)  7 - p. 103622 , 2024
Link: https://doi.org/10.1016/..
 
?
8

512P Predictive biomarkers and protein specific mismatch re..:

Le, H.M.L. ; Paiva, R.V.D.S. ; Farag, S....
Annals of Oncology.  35 (2024)  - p. S204 , 2024
Link: https://doi.org/10.1016/..
 
?
9

398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimum..:

Adenis, A. ; Chau, I. ; Ajani, J.A....
Annals of Oncology.  35 (2024)  - p. S161-S162 , 2024
Link: https://doi.org/10.1016/..
 
?
10

P1187: END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOST..:

Gleeson, M. ; Arias, C. ; Cunningham, D....
HemaSphere.  6 (2022)  - p. 1073-1074 , 2022
Link: https://doi.org/10.1097/..
 
?
11

Extranodal risk sites for CNS lymphoma: Review, good practi..:

Cordell, Suzanne C. ; Attygalle, A.D. ; Nicholson, E....
Clinical Radiology.  77 (2022)  - p. e13-e14 , 2022
Link: https://doi.org/10.1016/..
 
?
12

87P Infliximab use in patients with checkpoint inhibitor to..:

Zhang, S.H. ; Cartwright, E. ; Mullings, S....
Immuno-Oncology and Technology.  16 (2022)  - p. 100191 , 2022
Link: https://doi.org/10.1016/..
 
?
13

Chronic lymphocytic leukaemia and Richter's transformation:..:

Musanhu, E. ; Sharma, R.K. ; Attygalle, A....
Clinical Radiology.  76 (2021)  11 - p. 789-800 , 2021
Link: https://doi.org/10.1016/..
 
?
14

EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSP..:

Michalarea, V. ; Low, R. ; Kirkwood, A.A....
Hematological Oncology.  37 (2019)  S2 - p. 425-426 , 2019
Link: https://doi.org/10.1002/..
 
?
15

COMPARISON OF OUTCOMES BETWEEN PATIENTS WITH MYC REARRANGED..:

El‐Sharkawi, D. ; Sharma, S. ; Cook, L....
Hematological Oncology.  37 (2019)  S2 - p. 348-349 , 2019
Link: https://doi.org/10.1002/..
 
1-15